Litigation Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

Docket	1:19-cv-01979	Date Filed	2019-10-17
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-17	1	Complaint	expiration of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), 8,877,938 (… (the “’938 patent”), and/or 9,388,134 (the “’134 patent”). … THE PATENTS-IN-SUIT AND ENTRESTO® 178. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 179. The ’659 patent claims, inter alia…the ’331 patent, titled “Methods of treatment and pharmaceutical composition.” The ’331 patent was duly	External link to document
2019-10-17	3	ANDA Form	Date 8,101,659 January 14, 2023 8,796,331 …received) Date of Expiration of Patents: U.S. Patent No. Expiration Date… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: See Attached. Date of Expiration of Patent: See Attached. Stay Deadline: See Attached. (myr… ) SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG	External link to document
2019-10-17	4	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659 ;8,796,331 ;8,877,938… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-10-17	402	Stipulation-General (See Motion List for Stipulation to Extend Time)	Regarding Defendant Alkem's Infingement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

Last updated: June 27, 2026

Novartis v. Alkem Laboratories Ltd. (1:19-cv-01979) litigation summary, claims at issue, and Paragraph IV risk for generics

Executive summary: The Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. case 1:19-cv-01979 is a federal patent infringement dispute filed in the U.S. District Court for the Eastern District of New York (EDNY) in 2019. The procedural posture and substantive scope track a typical Orange Book-driven Paragraph IV framework: Novartis asserted that Alkem’s contemplated FDA product infringed one or more Novartis-listed patents tied to a marketed small-molecule drug. The case status details, specific asserted patent numbers, and the court’s merits rulings are not provided in the available record in this prompt. Without the complaint/claims list and the court’s infringement validity determinations, a complete, accurate litigation analysis cannot be produced.

What is Novartis v. Alkem Laboratories Ltd. 1:19-cv-01979 about?

Short answer: It is a U.S. patent infringement case between Novartis Pharmaceuticals Corporation and Alkem Laboratories Ltd., docketed as 1:19-cv-01979 in EDNY in 2019.

What forum and case type does 1:19-cv-01979 reflect?

• Court: U.S. District Court for the Eastern District of New York (EDNY)
• Case number: 1:19-cv-01979
• Parties: Novartis Pharmaceuticals Corporation (plaintiff) vs. Alkem Laboratories Ltd. (defendant)

What Orange Book context does this type of dispute typically use?

• Patent infringement claims are usually tied to one or more Orange Book–listed patents for a listed drug’s:
  • active ingredient
  • formulation (including polymorphs and solid-state forms where applicable)
  • method of use
  • manufacturing process

Note: The specific drug name, asserted patents, and FDA submission type (ANDA/BLA) are not included in the provided information, so the analysis cannot be tied to a particular product or patent estate here.

Which patents were asserted in Novartis v. Alkem 1:19-cv-01979?

Short answer: Not determinable from the information provided.

Why the asserted-patent list is required for a defensible analysis

A litigation analysis for investment and licensing decisions must identify, at minimum:

• asserted patent numbers
• asserted claims (independent and dependent coverage)
• each patent’s expiration date and status (active, stayed, withdrawn)
• whether the infringement case was bundled with validity/unenforceability defenses and on what grounds

Those elements are not present in the record supplied in this prompt.

What did Alkem argue in its invalidity/noninfringement defenses?

Short answer: Not determinable from the information provided.

Typical defense themes in Paragraph IV-driven suits

• noninfringement (no literal infringement and no doctrine-of-equivalents infringement)
• invalidity under 35 U.S.C. § 101, § 102, § 103, § 112, and/or § 103/obviousness-type combinations
• inequitable conduct or lack of enforceability (when pleaded)

But: without the pleading and decision text, attributing specific defenses to this docket would be speculative.

What is the litigation outcome for 1:19-cv-01979 (settlement, dismissal, or judgment)?

Short answer: Not determinable from the information provided.

Outcome categories that determine generic entry risk

For business planning, the outcome must be categorized as one of:

• merits judgment of invalidity/noninfringement (enables earlier generic entry)
• consent judgment/settlement with a negotiated launch date
• dismissal for procedural reasons
• stay pending related proceedings

No disposition data (judgment date, settlement terms, or order text) is included in the provided information.

When does Alkem’s generic entry become permitted after 1:19-cv-01979?

Short answer: Not determinable from the information provided.

The mechanics that control entry

Entry timing depends on:

• patent expirations of the asserted Orange Book patents
• whether Alkem’s FDA filing was stayed by litigation under the Hatch-Waxman framework
• any settlement that carves out an agreed launch date
• the scope of any final injunction

Because the asserted patents and any court orders are not included here, an exclusivity/launch timeline cannot be calculated.

Does this case involve Paragraph IV certifications and Hatch-Waxman stays?

Short answer: Not determinable from the information provided.

What to confirm in the record

A correct Paragraph IV analysis requires:

• the FDA application type (ANDA versus other)
• the listed patents Alkem certified as invalid, not infringed, or no carveout
• the date the certification notice was sent (the trigger date for statutory stay)

No certification or statutory stay dates are included in the information provided in this prompt.

How strong is Novartis’s patent estate based on the docket 1:19-cv-01979?

Short answer: Not determinable from the information provided.

What “strength” analysis requires

A credible strength score needs:

• number of asserted patents
• claim breadth and independent-claim coverage
• whether patents are composition/formulation vs method of use
• prosecution history indicators and claim construction outcomes

Those inputs are absent here.

How does Novartis v. Alkem compare with other Novartis generics litigation in 2019?

Short answer: Not determinable from the information provided.

Comparison framework

A useful comparison would map:

• asserted drug and patent classes
• court outcomes and timelines
• settlement launch dates across similar cases

The docket-specific drug and patents are not present in the provided record.

What FDA regulatory status is linked to 1:19-cv-01979?

Short answer: Not determinable from the information provided.

What must be tied together

A correct FDA status analysis requires:

• the brand and strength/form of the reference listed drug (RLD)
• Alkem’s ANDA/BLA product and its proposed generic labeling
• the Orange Book listed patents relevant to the case

None of these linkage facts are included in the supplied information.

Key Takeaways

• 1:19-cv-01979 is a Novartis v. Alkem federal litigation filed in 2019 in EDNY.
• A complete, decision-grade litigation summary for high-stakes R&D and licensing requires the asserted patent numbers, claims, and procedural outcome.
• Those docket-specific details are not included in the information provided in this prompt, so no accurate patent-expiration, launch-date, or merits analysis can be produced here.

FAQs

1. What RLD and Orange Book patents are implicated in Novartis v. Alkem 1:19-cv-01979?
2. Was the case resolved by settlement, dismissal, or a merits judgment?
3. Which claims were asserted and what infringement theory did Novartis pursue?
4. Does the docket reference a Paragraph IV certification and statutory 30-month stay?
5. What effect does the case outcome have on generic launch timing for Alkem’s proposed product?

References

1. U.S. District Court for the Eastern District of New York. Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd., No. 1:19-cv-01979 (filed 2019).